Science Explorer Back to mapMap
Discussion
Researcher · Atlantic Health System · United States

Eric D. Whitman

Eric D. Whitman publishes mostly in Oncology, Immunology and Molecular Biology, on topics such as CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers and Immunotherapy and Immune Responses.

ORCID 0000-0001-7529-067X OpenAlex
World rank
#561,659
of 7,710,434 ranked researchers
Rank in United States
#193,735
of 1,627,098
Works
126
Citations
5.2k
Citations per work
41.5
h-index
30
i10-index 50Top 11% in Oncology
Eric D. Whitman

What does Eric D. Whitman research?

Eric D. Whitman's work is mostly in Medicine (36%), Biochemistry, Genetics and Molecular Biology (18%), Immunology and Microbiology (12%).

Health Sciences: 46 works · 36.3% of their workMedicine: 46 works · 36.3% of their workOncology: 40 works · 32.1% of their workRadiology, Nuclear Medicine and Imaging: 5 works · 4.2% of their workEverything else: 43 works · 34.3% of their workLife Sciences: 37 works · 29.4% of their workBiochemistry, Genetics and Molecular Biology: 23 works · 17.9% of their workMolecular Biology: 11 works · 8.5% of their workBiotechnology: 7 works · 5.2% of their workGenetics: 5 works · 4.2% of their workImmunology and Microbiology: 14 works · 11.5% of their workImmunology: 14 works · 11.5% of their workTHEIR WORKEric D. Whitman126works
Life Sciences29%Health Sciences36%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine4636.3%
  2. Everything else4334.3%
    1. Biochemistry, Genetics and Molecular Biology2317.9%
    2. Immunology and Microbiology1411.5%
  1. 1Oncology32% of their works
  2. 2Immunology12% of their works
  3. 3Molecular Biology8% of their works
  4. 4Biotechnology5% of their works
  5. 5Radiology, Nuclear Medicine and Imaging4% of their works
  6. 6Genetics4% of their works

Research topics

Which keywords describe Eric D. Whitman's research?

The keywords of their largest research topics: Immunotherapy, Cancer Immunotherapy, Tumor Regression, CAR T Cells, Chimeric Antigen Receptor, Melanoma, Immune Checkpoint Blockade and PD-1 and PD-L1.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 21 words, with their numbers
  1. Immunotherapy793 topics
  2. Cancer Immunotherapy682 topics
  3. Tumor Regression572 topics
  4. CAR T Cells421 topic
  5. Chimeric Antigen Receptor421 topic
  6. Melanoma372 topics
  7. Immune Checkpoint Blockade351 topic
  8. PD-1 and PD-L1351 topic
  9. Gene Therapy282 topics
  10. Dendritic Cells261 topic
  11. Immunity261 topic
  12. Dermoscopy221 topic
  13. Skin Cancer221 topic
  14. BRAF gene151 topic
  15. Bacterial Therapy151 topic
  16. MAP Kinase151 topic
  17. Tumor Targeting151 topic
  18. AAV131 topic
  19. Viral Vectors131 topic
  20. Catheter-Related Infections101 topic
  21. Central Venous Catheterization101 topic

Where does Eric D. Whitman work?

Eric D. Whitman's main affiliation in the publication record is Atlantic Health System, United States.

How many publications and citations does Eric D. Whitman have?

OpenAlex counts 126 works and 5,229 citations for Eric D. Whitman, an h-index of 30, ranking #561,659 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Eric D. Whitman. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.